Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: A matched case-control study on 174 patients

Leukemia

Volumn 28, Issue 12, 2014, Pages 2311-2316

  Palladini, G ^a,b   Milani, P ^a,b   Foli, A ^a,b   Rosin, M Vidus ^a,b   Basset, M ^a,b   Lavatelli, F ^a   Nuvolone, M ^a,b   Obici, L ^a,b   Perlini, S ^b   Merlini, G ^a,b  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; MELPHALAN; NATRIURETIC FACTOR; NATRIURETIC PEPTIDE TYPE B; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; IMMUNOGLOBULIN LIGHT CHAIN; PYRAZINE DERIVATIVE;

ADD ON THERAPY; ADULT; AGED; AMYLOIDOSIS; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG MEGADOSE; HEART FAILURE; HEART FUNCTION; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; IMMUNOGLOBULIN LIGHT CHAIN AMYLOIDOSIS; INTERMEDIATE RISK PATIENT; KIDNEY FUNCTION; LIGHT CHAIN; MAJOR CLINICAL STUDY; NEW YORK HEART ASSOCIATION CLASS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE; CASE CONTROL STUDY; METABOLISM; MIDDLE AGED; MORTALITY;

AGED; AMYLOIDOSIS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; CASE-CONTROL STUDIES; DEXAMETHASONE; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; MELPHALAN; MIDDLE AGED; PYRAZINES; TREATMENT OUTCOME;

EID: 84925286756     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.227     Document Type: Article

References (46)

1. Merlini G, Stone M. Dangerous small B-cell clones. Blood 2006; 108: 2520-2530.
2. Merlini G, Palladini G. Light chain amyloidosis: the heart of the problem. Haematologica 2013; 98: 1492-1495.
3. Wechalekar AD, Schonland SO, Kastritis E, Gillmore JD, Dimopoulos MA, Lane T et al. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood 2013; 121: 3420-3427.
4. Liao R, Jain M, Teller P, Connors L, Ngoy S, Skinner M et al. Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts. Circulation 2001; 104: 1594-1597.
5. Palladini G, Campana C, Klersy C, Balduini A, Vadacca G, Perfetti V et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 2003; 107: 2440-2445.
6. Palladini G, Lavatelli F, Russo P, Perlini S, Perfetti V, Bosoni T et al. Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood 2006; 107: 3854-3858.
7. Guan J, Mishra S, Shi J, Plovie E, Qiu Y, Cao X et al. Stanniocalcin1 is a key mediator of amyloidogenic light chain induced cardiotoxicity. Basic Res Cardiol 2013; 108: 378.
8. Diomede L, Rognoni P, Lavatelli F, Romeo M, Del Favero E, Cantù L et al. A Caenorhabditis elegans-based assay recognizes immunoglobulin light chains causing heart amyloidosis. Blood 2014; 123: 3543-3552.
9. Merlini G, Wechalekar AD, Palladini G. Systemic light chain amyloidosis: an update for treating physicians. Blood 2013; 121: 5124-5130.
10. Gertz MA. How to manage primary amyloidosis. Leukemia 2012; 26: 191-198.
11. Ocio EM, Richardson PG, Rajkumar SV, Palumbo A, Mateos MV, Orlowski R et al. New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). Leukemia 2014; 28: 525-542.
12. Sitia R, Palladini G, Merlini G. Bortezomib in the treatment of AL amyloidosis: targeted therapy? Haematologica 2007; 92: 1302-1307.
13. Bianchi G, Oliva L, Cascio P, Pengo N, Fontana F, Cerruti F et al. The proteasome load vs. capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition. Blood 2009; 113: 3040-3049.
14. Oliva L, Pengo N, Palladini G, Cascio P, Pasqualetto E, Merlini Get al. Proteasome activity and stress in light chain amyloidosis. Amyloid 2010; 17: 99.
15. Kastritis E, Anagnostopoulos A, Roussou M, Toumanidis S, Pamboukas C, Migkou M et al. Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone. Haematologica 2007; 92: 1351-1358.
16. Wechalekar A, Lachmann H, Offer M, Hawkins P, Gillmore J. Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease. Haematologica 2008; 93: 295-298.
17. Reece D, Sanchorawala V, Hegenbart U, Merlini G, Palladini G, Fermand J et al. Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study. Blood 2009; 114: 1489-1497.
18. Reece DE, Hegenbart U, Sanchorawala V, Merlini G, Palladini G, Bladé J et al. Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. Blood 2011; 118: 865-873.
19. Dubrey SW, Reece DE, Sanchorawala V, Hegenbart U, Merlini G, Palladini G et al. Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects. QJM 2011; 104: 957-970.
20. Kastritis E, Wechalekar A, Dimopoulos M, Merlini G, Hawkins P, Perfetti V et al. Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol 2010; 28: 1031-1037.
21. Landau H, Hassoun H, Rosenzweig MA, Maurer M, Liu J, Flombaum C et al. Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis. Leukemia 2013; 27: 823-828.
22. Mikhael JR, Schuster SR, Jimenez-Zepeda VH, Bello N, Spong J, Reeder CB et al. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood 2012; 119: 4391-4394.
23. Venner CP, Lane T, Foard D, Rannigan L, Gibbs SD, Pinney JH et al. Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood 2012; 119: 4387-4390.
24. Palladini G, Perfetti V, Obici L, Caccialanza R, Semino A, Adami F et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood 2004; 103: 2936-2938.
25. Palladini G, Russo P, Nuvolone M, Lavatelli F, Perfetti V, Obici L et al. Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis. Blood 2007; 110: 787-788.
26. Palladini G, Milani P, Foli A, Obici L, Lavatelli F, Nuvolone M et al. Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach. Haematologica 2014; 99: 743-750.
27. Palladini G, Merlini G. Transplantation vs. conventional-dose therapy for amyloidosis. Curr Opin Oncol 2011; 23: 214-220.
28. Jaccard A, Moreau P, Leblond V, Leleu X, Benboubker L, Hermine O et al. Highdose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 2007; 357: 1083-1093.
29. Palladini G, Anesi E, Perfetti V, Obici L, Invernizzi R, Balduini C et al. A modified high-dose dexamethasone regimen for primary systemic (AL) amyloidosis. Br J Haematol 2001; 113: 1044-1046.
30. Dhodapkar M, Hussein M, Rasmussen E, Solomon A, Larson R, Crowley J et al. Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628. Blood 2004; 104: 3520-3526.
31. Dietrich S, Schönland S, Benner A, Bochtler T, Kristen A, Beimler J et al. Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvement. Blood 2010; 116: 522-528.
32. Palladini G, Merlini G. Uniform risk-stratification and response criteria are paving the way to evidence-based treatment of AL amyloidosis. Oncology (Williston Park) 2011; 257: 637-638.
33. Comenzo RL, Reece D, Palladini G, Seldin D, Sanchorawala V, Landau H et al. Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia 2012; 26: 2317-2325.
34. Arbustini E, Verga L, Concardi M, Palladini G, Obici L, Merlini G. Electron and immuno-electron microscopy of abdominal fat identifies and characterizes amyloid fibrils in suspected cardiac amyloidosis. Amyloid 2002; 9: 108-114.
35. Brambilla F, Lavatelli F, Di Silvestre D, Valentini V, Rossi R, Palladini G et al. Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue. Blood 2012; 119: 1844-1847.
36. Palladini G, Russo P, Bosoni T, Verga L, Sarais G, Lavatelli F et al. Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine. Clin Chem 2009; 55: 499-504.
37. Dispenzieri A, Gertz M, Kyle R, Lacy M, Burritt M, Therneau T et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol 2004; 22: 3751-3757.
38. Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 2012; 30: 989-995.
39. Palladini G, Malamani G, Co F, Pistorio A, Recusani F, Anesi E et al. Holter monitoring in AL amyloidosis: prognostic implications. Pacing Clin Electrophysiol 2001; 24: 1228-1233.
40. Caccialanza R, Palladini G, Klersy C, Cena H, Vagia C, Cameletti B et al. Nutritional status of outpatients with systemic immunoglobulin light-chain amyloidosis 1. Am J Clin Nutr 2006; 83: 350-354.
41. Caccialanza R, Palladini G, Klersy C, Cereda E, Bonardi C, Cameletti B et al. Nutritional status independently affects quality of life of patients with systemic immunoglobulin light-chain (AL) amyloidosis. Ann Hematol 2012; 91: 399-406.
42. Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol 2012; 30: 4541-4549.
43. Rourke M, Anderson KC, Ghobrial IM. Review of clinical trials conducted in Waldenstrom macroglobulinemia and recommendations for reporting clinical trial responses in these patients. Leuk Lymphoma 2010; 51: 1779-1792.
44. Gertz MA, Merlini G. Definition of organ involvement and response to treatment in AL amyloidosis: an updated consensus opinion. Amyloid 2010; 17: 48-49.
45. Mahmood S, Palladini G, Sanchorawala V, Wechalekar A. Update on treatment of light chain amyloidosis. Haematologica 2014; 99: 209-221.
46. Gasparetto C, Sanchorawala V, Snyder R, Matous J, Terebelo H, Janakiraman N et al. Use of melphalan (M)/dexamethasone (D)/bortezomib in AL amyloidosis. J Clin Oncol 2010; 28: 8024-8024.